CHAPEL HILL - The University of North Carolina’s two medical schools and their cancer centers have signed a memorandum of understanding that creates a partnership to advance cancer research and bring leading-edge treatment to North Carolinians.
CHAPEL HILL – The governance committee of the University Cancer Research Fund has established first-year spending priorities for the state’s initial $25 million investment at the University of North Carolina at Chapel Hill.
Stephen Frye, PhD, former worldwide head of discovery medicinal chemistry at GlaxoSmithKline, will lead the new Center for Integrative Chemical Biology and Drug Discovery at the University of North Carolina at Chapel Hill.
Winston-Salem Journal Editorial, August 8, 2007
Editorials, Charlotte Observer, August 3, 2007
Funding will improve quality of life for cancer patients, families statewide